Xiaodong Zhang

TL;DR: Furmonertinib (AST2818) is an irreversible, selective, third-generation EGFR tyrosine-kinase inhibitor as discussed by the authors , which is a new potential treatment option for this population.

TL;DR: In this article , the authors reported the CNS efficacy of furmonertinib compared with gefitinib in untreated EGFR-sensitizing mutation-positive NSCLC from the FURLONG study.

TL;DR: Wang et al. as discussed by the authors identified two differently expressed m6ArlncRNAs, AC008870.2 and EMX2OS, as independent risk factors for overall survival of CC patients, by applying stringent variable selection procedure to data from the Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma project.

TL;DR: 5/6Nx mice have enhanced neurovascular transmission and vasoconstriction from an impaired EDH anticontractile component before vascular structural changes, which depend on an enhanced sympathetic discharge that impairs the expression of Cx43 in gap junctions at MEJs, thereby interrupting EDH responses that normally moderate vascular tone.

TL;DR: Wang et al. as discussed by the authors proposed serum cystatin C-related criteria (CyNA) for neonatal AKI, which is a robust and sensitive biomarker for identifying AKI in neonates who are at an elevated risk of in-hospital mortality.